CBAY insider transaction filings
CymaBay Therapeutics, Inc. — 32 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-03-22. Screen CBAY transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CBAY between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — CymaBay Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-03-22 | 4 | Loewy Caroline M — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 27,705 (derivative) · Disposition to issuer (D): 49,245 (derivative) · +4 more | EDGAR |
| 2024-03-22 | 4 | McWherter Charles — President of R&D | Disposition to issuer (D): 15,000 · Disposition to issuer (D): 31,938 · Disposition to issuer (D): 91,666 (derivative) · Disposition to issuer (D): 51,750 (derivative) · Disposition to issuer (D): 44,084 (derivative) · Disposition to issuer (D): 97,222 (derivative) · +7 more | EDGAR |
| 2024-03-22 | 4 | Lefebvre Eric — Director | Disposition to issuer (D): 115,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 14,010 (derivative) | EDGAR |
| 2024-03-22 | 4 | Dorling Janet — Director | Disposition to issuer (D): 55,000 (derivative) · Disposition to issuer (D): 67,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 14,010 (derivative) | EDGAR |
| 2024-03-22 | 4 | Shantharam Harish — Chief Financial Officer | Disposition to issuer (D): 20,125 · Disposition to issuer (D): 360,000 (derivative) · Disposition to issuer (D): 74,750 (derivative) | EDGAR |
| 2024-03-22 | 4 | Dickinson Klara — Chief Regulatory Officer | Disposition to issuer (D): 21,000 · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 138,312 (derivative) · Disposition to issuer (D): 328,299 (derivative) · Disposition to issuer (D): 66,500 (derivative) · +3 more | EDGAR |
| 2024-03-22 | 4 | Quinlan Paul T — General Counsel | Disposition to issuer (D): 41,824 · Disposition to issuer (D): 28,438 · Disposition to issuer (D): 233,176 (derivative) · Disposition to issuer (D): 22,167 (derivative) · Disposition to issuer (D): 107,000 (derivative) · Disposition to issuer (D): 215,000 (derivative) · +1 more | EDGAR |
| 2024-03-22 | 4 | Wills Robert James — Director | Disposition to issuer (D): 30,000 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 27,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · +8 more | EDGAR |
| 2024-03-22 | 4 | Shah Sujal — Chief Executive Officer, Director | Disposition to issuer (D): 310,420 · Disposition to issuer (D): 96,250 · Disposition to issuer (D): 88,351 (derivative) · Disposition to issuer (D): 39,375 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 47,916 (derivative) · +9 more | EDGAR |
| 2024-03-22 | 4 | WIGGANS THOMAS G — Director | Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 67,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 14,010 (derivative) | EDGAR |
| 2024-03-22 | 4 | EMSTER KURT VON — Director | Disposition to issuer (D): 90,000 · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · +7 more | EDGAR |
| 2024-03-15 | 4 | Shah Sujal — Chief Executive Officer, Director | Option exercise (M): 11,649 @ $10 · Option exercise (M): 14,625 @ $1.06 · Option exercise (M): 52,084 @ $1.72 · Option exercise (M): 18,899 @ $9.21 · Option exercise (M): 3,125 @ $11.69 · Option exercise (M): 14,372 @ $8.43 · +12 more | EDGAR |
| 2024-03-15 | 4 | Quinlan Paul T — General Counsel | Option exercise (M): 41,824 @ $7.89 · Option exercise (M): 41,824 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Dorling Janet — Director | Option exercise (M): 6,000 @ $4.63 · Sale (S): 6,000 @ $31.97 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Shantharam Harish — Chief Financial Officer | Grant/award (A): 20,125 @ $0 · Grant/award (A): 74,750 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Dickinson Klara — Chief Regulatory Officer | Grant/award (A): 21,000 @ $0 · Grant/award (A): 78,000 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | McWherter Charles — President of R&D | Grant/award (A): 31,938 @ $0 · Grant/award (A): 118,625 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Quinlan Paul T — General Counsel | Grant/award (A): 28,438 @ $0 · Grant/award (A): 105,625 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Shah Sujal — Chief Executive Officer, Director | Grant/award (A): 96,250 @ $0 · Grant/award (A): 357,500 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Wills Robert James — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Dorling Janet — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Loewy Caroline M — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Lefebvre Eric — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | EMSTER KURT VON — Director | Grant/award (A): 14,010 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | McWherter Charles — President of R&D | Option exercise (M): 2,250 @ $1.06 · Sale (S): 2,250 @ $23.67 · Option exercise (M): 2,778 @ $1.72 · Sale (S): 2,778 @ $23.66 · Option exercise (M): 1,916 @ $1.82 · Sale (S): 1,916 @ $23.66 · +9 more | EDGAR |
| 2024-01-16 | 4 | Menold Daniel — Vice President, Finance | Option exercise (M): 10,000 @ $4.05 · Sale (S): 10,000 @ $23.58 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | Quinlan Paul T — General Counsel | Option exercise (M): 5,000 @ $2.94 · Sale (S): 5,000 @ $23.58 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-01-10 | 4 | Dorling Janet — Director | Option exercise (M): 6,000 @ $4.63 · Sale (S): 6,000 @ $23.86 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | McWherter Charles — President of R&D | Option exercise (M): 4,828 @ $5 · Sale (S): 4,828 @ $21.49 · Option exercise (M): 6,504 @ $5 · Sale (S): 6,504 @ $21.48 · Option exercise (M): 704 (derivative) @ $0 · Option exercise (M): 234 (derivative) @ $0 · +2 more | EDGAR |
| 2023-12-15 | 4 | Menold Daniel — Vice President, Finance | Option exercise (M): 10,000 @ $4.05 · Sale (S): 10,000 @ $21.98 · Option exercise (M): 11,497 @ $8.43 · Sale (S): 11,497 @ $21.99 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 11,497 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Quinlan Paul T — General Counsel | Option exercise (M): 5,000 @ $2.94 · Sale (S): 5,000 @ $21.98 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CymaBay Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-03-22 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-21 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CBAY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →